State of Brandenburg sponsors BELANO medical’s development of new prophylactic product -
Hennigsdorf b. Berlin, 4 February 2021 – Worldwide, there is great clinical demand for nonantibiotic options to target and safely remove pathogenic germs from the skin of patients suffering from atopic eczema patients. Remedies such as antibiotics or antiseptics, which we have so far relied on, are in many cases not indicated, lack effectiveness, or when used have complex side effects and often negative consequences such as development of resistance or changes to the makeup of the skin microbiome. For this reason, BELANO medical AG has initiated development of a highly innovative topical (for external application) class IIa medical product for the treatment of atopic eczema.
Hennigsdorf b. Berlin, 4 February 2021 – Worldwide, there is great clinical demand for nonantibiotic options to target and safely remove pathogenic germs from the skin of patients suffering from atopic eczema patients. Remedies such as antibiotics or antiseptics, which we have so far relied on, are in many cases not indicated, lack effectiveness, or when used have complex side effects and often negative consequences such as development of resistance or changes to the makeup of the skin microbiome. For this reason, BELANO medical AG has initiated development of a highly innovative topical (for external application) class IIa medical product for the treatment of atopic eczema.